Modeling and simulation (M&S) has a proven track record. Across biopharma, fine chemicals, food and beverage, and energy sectors, it reduces experimental burden, accelerates scale-up, improves process quality, and de-risks decisions that would otherwise require costly physical trials. Regulators encourage it. Industry leaders champion it. The ROI is well documented.

Organizations stall with M&S because of barriers that live closer to home: in budgets, in data infrastructure, in organizational culture, and in the question of what it takes to trust a model enough to act on it.

In this four-part blog series, we explore each of those barriers directly.

We start with cost and infrastructure, specifically the true cost of building in-house M&S capability, and why access to that capability often matters more than ownership of it. From there, we turn to data readiness, examining what it takes to prepare your process data for AI-assisted and data-driven models before you can expect those models to deliver.

Part three examines cultural resistance, the human side of adoption, and why even technically sound M&S programs can stall when organizational buy-in is missing. Finally, we address validation and trust: what it takes to establish model credibility, and why that credibility is the foundation that makes everything else possible.

Each article stands on its own, but together they paint a complete picture of why the gap between M&S potential and M&S practice persists, and what it takes to close it.